Tag:

Sanofi

Latest Headlines

Latest Headlines

Lower-cost Praluent dose may be Sanofi's weapon against Amgen's rival PCSK9 med

Payers have promised a fight over the price of PCSK9 drugs, a new class of cholesterol fighters expected to be a pricey proposition.

Sanofi splurges $245M on Retrophin's speedy-review voucher

Retrophin is selling its recently acquired coupon for a speedy FDA approval to Sanofi for $245 million in cash.

Revving up for price war with Amgen, Sanofi plots low-cost starter dose of PCSK9 med

Payers have promised a fight over the price of PCSK9 drugs, a new class of cholesterol fighters. Drugmakers in the field--including frontrunners Amgen and Sanofi--prepared for that fight. And now, analysts think they've defined the battle lines.

Sanofi buys into NeuroVive's cardio drug in Korea

Sanofi is betting on the promise of NeuroVive Pharmaceutical's top prospect, buying the South Korean rights to the biotech's Phase III cardiovascular drug.

Regeneron's arthritis drug aces Phase III with the FDA in sight

Regeneron posted another round of clinical successes from its sweeping Phase III rheumatoid arthritis program, plotting to submit its Sanofi-partnered antibody for regulatory scrutiny this year.

Sanofi seeks the next Teenage Idol in meningitis vaccine campaign

Only about 30% of teens receive a second meningitis shot at age 16 as recommended by the CDC, and for vaccine maker Sanofi Pasteur, that's a problem. But the French drugmaker is hoping it can change that, and to do so, it's teaming up with a teen idol.

Sanofi doubles down on Selecta collaboration, adding $300M in fresh incentives

Sanofi is taking its three-year-old development collaboration with Selecta Biosciences another big step forward, taking an option on a "negative vaccine" program for celiac disease and putting another $300 million on the table in prospective milestones and research support for a successful program.

Lucky 7 diabetes meds to join blockbuster club by 2020

Which diabetes med is likely to be on top in 2020? According to FirstWord Pharma, that would be--surprise!--Lantus, albeit as a $5 billion shadow of its former self. Januvia should keep its hold on second prize with almost $4 billion, while Novo Nordisk's NovoRapid and Lilly's Humalog remain in the top 5 with $3.6 billion and $3.04 billion in sales.

Analysts 'skeptical' Sanofi can turn around Afrezza launch, but DTC ads are coming

Afrezza wasn't expected to be the spinach that would give Sanofi's diabetes business instant, superhuman strength. But the inhaled insulin, launched in February under a marketing deal with MannKind, was supposed to help fuel sales growth.

Big Pharma's cardiovascular sales ain't what they used to be

Slumping sales for cardiovascular drugs isn't exactly a new phenomenon for Big Pharma, with some of the industry's top drugmakers suffering from recent patent expirations. But a new report shows which CV franchises have been hurt the most.